FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase inhibitor programs, including investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. Assembly Bio will receive a $35 million payment for Gilead's exercise of the combined HSV program option. Gilead will receive an exclusive license to ABI-5366 and ABI-1179 and will have the sole right and responsibility for further clinical development and commercialization of these programs.
Assembly Bio remains eligible for up to $330 million in regulatory and commercial milestones, as well as tiered royalties on net sales.
For More Such Health News, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
